Another cancer drug by Janssen unlikely to be available in Germany
Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,
Category: News and updates
Lung cancer drug taken off German market because of no additional benefit rating
On 25 August 2022, Janssen has announced that they have withdrawn the lung cancer drug Rybrevant (amivantamab) from the German market with
Federal Cabinet has agreed new law to stabilise SHI finances
Despite strong opposition and critique raised by almost all stakeholders, the draft law on the financial stabilization of statutory health insurance (GKV-FinStG),
New EU regulation for in-vitro diagnostics – the end of laboratory-developed tests?
Following on from the EU regulation for medical devices (MDR) that came into force over one year ago, this week I am
AOK raises further critique on draft law to stabilise SHI finances
Recently, I wrote about the planned reforms that the German Health Minister, Karl Lauterbach, wants to introduce with the act to stabilise